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Abstract
The Aurora family of serine/threonine kinases plays an important role in 
chromosome alignment, segregation and cytokinesis during mitosis. Recent studies have 
found aberrant expression of Aurora kinases in a variety of human solid tumors and 
hematological malignancies, suggesting they have a role in carcinogenesis. This review 
highlights the function of Aurora kinases in the regulation of mitosis and presents the 
rationale for these kinases as an anti-cancer target. We also review recently developed 
inhibitors of Aurora kinases.
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1. Introduction
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2The Aurora family of serine/threonine kinases plays an important role in 
chromosome alignment, segregation and cytokinesis during mitosis. The family has
three members: Aurora A, B and C, which share 67-76% amino acid sequence identity 
in their catalytic domains, but show little N-terminus similarity [1,2]. Aurora A localizes 
on centrosomes and has a crucial role in each step of mitosis [2]. Aurora B is a 
chromosomal passenger protein that localizes at centromeres during the prometaphase 
and subsequently relocates to midzone microtubules and midbodies during anaphase 
and telophase [1,3]. Aurora B is involved in chromosome alignment, 
kinetochore-microtubule biorientation, activation of the spindle assembly checkpoint 
and cytokinesis [1,3]. Aurora C is specifically expressed in the testis and plays a role in 
spermatogenesis [4]. It was recently found that Aurora C also acts as a chromosomal
passenger protein and might compensate for lost Aurora B function [5]. 
Aurora A and B are overexpressed in a variety of solid tumors, including those
from colon [6,7], breast [7-10], prostate [11], pancreas [12], thyroid [13], and head and 
neck [14]. In addition, it has been found recently that Aurora A and B are aberrantly
expressed in hematological malignancies including acute myelogenous leukemia 
(AML), chronic myelogenous leukemia (CML), and acute lymphoblastic leukemia 
(ALL) [15]. The significance of aberrant expression of Aurora kinases remains elusive, 
although high levels are associated with advanced clinical stage and poor prognosis in 
individuals with colorectal [7] and prostate [11] cancers and head and neck 
squamous-cell carcinoma [14]. Other studies have found aberrant expression of Aurora 
A kinase in early stage breast and ovarian cancers [16,17 ]. Examination of the 
relationship between Aurora C and cancer is limited; however several studies have 
found aberrant expression of Aurora C in colorectal, breast, and prostate cancers [5, 18]. 
3These observations suggest that Aurora kinases might be a promising molecular target 
for cancer treatment. A number of small-molecule inhibitors targeting Aurora kinases 
have been developed, which include MK0457 (formerly VX-680) [19], AZD1152 
[20-22], MLN8054 [23], and PHA-739358 [24]. These compounds showed anti-tumor 
activity in preclinical studies and clinical trials are ongoing in the United States and 
Europe.
2. Biological function of Aurora kinases.
Aurora A. Aurora A is expressed widely in proliferating normal tissues, with expression 
being highest at the G2/M phase of the cell cycle; levels are then rapidly decreased by 
degradation via the ubiquitin-proteasome pathway [25,26]. Aurora A localizes on 
duplicated centrosomes from the end of S phase to the beginning of the following G1 
phase and plays a crucial role in each step of mitosis. For example, it regulates the 
maturation of centrosomes by interacting with transforming acid coiled-coil (TACC) 
proteins; activated TACC is recruited to the centrosome and forms a complex with 
microtubule-associated proteins such as Msps/XMAP215, centrosomin, and -tubulin, 
leading to growth of microtubules, which consequently promote maturation of the 
centrosome [Fig 1A, 27-31]. 
Aurora A also regulates mitotic entry by interacting with Ajuba, a LIM protein [32]: the 
phosphorylated form of Ajuba binds to Aurora A, leading to activation of Aurora A at 
late G2 phase. Interaction of Ajuba and Aurora A is essential for recruitment of the
cyclin B1/CDK1 complex to the centrosome, where it becomes activated and commits 
cells to mitosis [Fig 1B, 32]. 
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maximum expression at the G2/M phase of the cell cycle [33]. Similar to Aurora A 
kinase, levels of Aurora B protein are regulated by proteasomal degradation [34]. 
Aurora B kinase belongs to the chromosome passenger protein family, which comprises
inner centrosome protein (INCENP), survivin, and borealin [35]. These proteins form a 
chromosome passenger complex and localize on the kinetochores from the prophase to 
the metaphase and on the central spindle and the midbody in cytokinesis [1]. Aurora B 
is activated by autophosphorylation after association with the passenger complex 
[36-40]. Inhibition of Aurora B by RNA interference showed that it is required for 
cytokinesis [41], where its important function is regulation of the kinesin-like protein 
pavarotti, which is essential for establishment of the central spindle during anaphase 
[Fig 2A]. Disruption of Aurora B caused mis-localization of pavarotti, resulting in 
cytokinesis defect [42]. Cytoskeletal proteins in the cleavage furrow, such as myosin II 
regulatory light chain, vimentin, desmin and glial fibrillary acidic protein, are also 
substrates of Aurora B and participate in filament formation and cytokinesis [43-45]. 
Other functions of Aurora B relate to histone modification: it phophorylates histone H3 
on Ser10 [41] and Ser28 [46], and centromere protein A on Ser7 [47]. Phosphorylation 
of histone H3 on Ser10 dissociates heterochromatin protein 1 (HP1) from 
heterochromatin at the onset of mitosis [48]; however, the biological effect of HP1
release remains unknown. 
Aurora B is also implicated in microtubule-kinetochore attachment by interacting with 
the kinetochore-specific histone H3 variant CENP-A [Fig 2B, 49]. CENP-A is first 
phosphorylated on Ser7 by Aurora A during the prophase, recruiting Aurora B to the 
inner centromere [50]. Aurora B then maintains phosphorylation of CENP-A on Ser7 
5from late prophase through metaphase and regulates kinetochore functions [50]. 
Other Aurora B substrates include BubR1 and Mad2, mitotic checkpoint proteins. 
Inhibition of Aurora B by RNA interference compromised the mitotic checkpoint, 
resulting in increased numbers of aneuploid cells [51]. 
Aurora C. Aurora C is a much less extensively studied member of the Aurora kinase
family. Aurora C is localized to Chr19q13 and was first isolated from a testis cDNA 
library [52]. Aurora C is specifically expressed in testis, as measured by northern blot 
analysis, and is believed to play an important role in spermatogenesis [4]. Recent 
studies found that Aurora C is also a chromosomal passenger protein and binds to 
INCENP, for which it has lower affinity than Aurora B [5]. In addition, forced 
expression of Aurora C rescued an Aurora-B-silenced phenotype of HeLa cells in vitro, 
suggesting that Aurora C might be able to compensate for lost Aurora B function [5].
3. Aurora kinases and cancer. 
Aurora A. Aurora A is located on chromosome 20q13.2, a region commonly amplified
in human malignancies, including those from colon, breast, pancreas, ovary, and 
prostate [6,7]. Although aberrant expression of Aurora A has been found in various 
tumor types, it does not always correlate with gene amplification. For example, 
amplification of Aurora A was found in only 3% of hepatocellular carcinomas (HCCs), 
although more than 60% of HCCs overexpressed Aurora A [53], suggesting that 
mechanisms other than gene amplification may contribute to the aberrant expression. 
Forced expression of Aurora A gene in murine NIH 3T3 cells induced abnormal 
centrosome number (amplification) and transformation in vitro [54]. In addition, forced
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centrosome abnormality, as well as induction of aneuploidy [7]. Other groups also found 
that conditional expression of Aurora A in murine mammary epithelium induced 
accumulation of binucleated cells and transformation when p53 was deleted [55]. These 
findings suggest that Aurora A can act as an oncogene. 
Interestingly, Aurora A interacts with and inactivates the tumor suppressor p53; Aurora 
A phosphorylates p53 on Ser315, facilitating MDM-2-mediated degradation of p53 in 
cancer cell lines [56]. Aurora A phosphorylates p53 on Ser215 and abrogates its 
DNA-binding ability, resulting in inhibited transcriptional activity [57]. 
Aurora A also interacts with the breast cancer susceptibility gene BRCA 1. Aurora A 
colocalizes with BRCA 1 in centrosomes and phophorylates BRCA 1 on Ser308, 
leading to impairment of its function as a G2/M checkpoint keeper [58]. Thus, it may 
also be involved in the carcinogenesis of breast cancer. 
Overexpression of Aurora A causes resistance to Taxol-mediated apoptosis in cancer 
cells. Taxol, a tubulin depolymerizing agent, activates the spindle checkpoint in HeLa 
cells, but this is overridden by Aurora A, resulting in escape from apoptosis [59].
Aurora B. The contribution of Aurora B to carcinogenesis has been less studied than 
that of Aurora A. Aurora B is located on chromosome 17p13.1, a region not typically
amplified in human malignancies; however, overexpression of Aurora kinase B has been 
shown in a variety of human cancers, including glioblastoma multiforme [60], 
malignant mesothelioma [61], and hematological malignancies [15]. High levels of 
Aurora B are associated with adverse clinical outcomes in patients with endometrial 
carcinoma [62]. Forced expression of Aurora B in Chinese hamster embryo cells 
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constitutive expression of phosphorylated (p)-histone H3 on Ser10 [63], suggesting that 
Aurora B can act as an oncogene.
Aurora C. The involvement of Aurora C in carcinogenesis has been the least explored 
of all the Aurora kinase family. The few available studies found that Aurora C was 
overexpressed in colorectal, breast, and prostate cancers [5, 18]. The level of expression 
of Aurora C correlated with the degree of dysplastic change in colorectal cancer cells 
[18]. Forced expression of Aurora C in HeLA cells produced polyploidy, which was 
augmented by inactivation of p53 [64]. These observations suggest that Aurora C might 
be a promising molecular target for cancer treatment.  
4. Development of Aurora kinase inhibitors. Evidence linking Aurora kinases to 
malignancies has raised the possibility of targeting these kinases for cancer therapy. A 
number of small-molecule inhibitors with activity against Aurora A and/or B have been 
developed. The first generation of this class of compound included Hesperadin, 
ZM447439, and MK0457 (formally VX-680). The next generation of Aurora kinase 
inhibitor has been developed and includes AZD1152, a potent and selective inhibitor of 
Aurora B kinase; MLN8054, an orally available selective inhibitor of Aurora A kinase;
and the pan-Aurora kinase inhibitor PHA-739358. Some of these agents are undergoing 
evaluation in clinical trials.  
Hesperadin. Hesperdin (Boehringer Ingelheim) is a novel indolinone with specific
activity against Aurora B kinase, as it was shown to inhibit p-histone H3 with an IC50 of 
250 nM. It was the first proven inhibitor of Aurora kinase B, but has not been verified in 
8clinical trials. Hesperadin induced polyploidy in HeLa cells [Table 1, 65].
ZM447439. ZM447439 (AstraZeneca) is an ATP-competitive selective inhibitor of 
Aurora kinase A and B (IC50 110 nM and 130 nM for Aurora A and B, respectively), 
which compromises chromosomal alignment and cell division as well as mitotic 
checkpoint in HeLa, A549, MCF-7 and DLD1 cells [Table 1, 51]. The phenotypes 
induced by ZD447439 were due to Aurora B inhibition, as determined by RNA 
interference experiments [51]. In addition, a recent study found that ZM447439 was 
active against hematological malignancies including AML and Philadelphia
chromosome-positive ALL [15]. This study also found that cells expressing wild-type
p53 were more sensitive to ZM447439-mediated growth inhibition than cells possessing 
the mutated p53 gene. These observations suggest that the p53-dependent post-mitotic 
checkpoint played an important role in Aurora kinase inhibitor-mediated apoptosis. 
ZM447439 has not been developed in clinical trials.
MK0457. MK0457 (VX-680; Merk/Vertex) is an ATP-competitive pan-Aurora 
kinase inhibitor (IC50 0.6, 18, and 4.6 nM for Aurora A, B, and C, respectively) [Table 1, 
19]. In vitro study showed that MK0457 induced endoreduplication in cancer cells, a 
characteristic feature of phenotype mediated by inhibition of Aurora B kinase by RNA 
interference. Preclinical study showed that MK0457 inhibited proliferation of human 
myelogenous leukemia HL60 and colon cancer HCT116 cells in a murine xenograft 
model [19]. MK0457 effectively inhibited colony formation of freshly isolated AML 
cells with internal tandem duplication mutations in the fms-like tyrosine kinase (FLT3) 
gene [19]. MK0457 possesses many off-targets including FLT3 kinase. Interestingly, 
MK0457 was able to inhibit imatinib- or dasatinib-resistant ABL kinase mediated by 
T315I mutation [66]. A recent clinical study showed that MK0457 was active in 
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mutation [66]. A phase 1 clinical trial of MK0457 in 22 heavily pre-treated patients 
found a recommended dose of 10 mg/m/h, continuous 24 h infusion for 5 days every 28 
days. Neutropenia was the dose-limiting toxicity. One patient with pancreatic cancer 
and another with non-small-cell lung cancer achieved stable disease as their best 
response, which lasted over 6 months [67].
AZD1152. AZD1152 (AstraZeneca) is a novel acetanilide-substituted 
pyrazole-aminoquinazoline prodrug that is converted rapidly to the active drug 
AZD1152 hydroxy-QPA (AZD1152-HQPA) in human plasma [20]. AZD1152-HQPA is 
a specific and selective inhibitor of the enzymatic activity of Aurora B kinase (IC50 0.37 
nM versus 1368 nM for Aurora B and A kinases, respectively); the inhibitor had even 
lower activity against a panel of more than 50 other serine-threonine and tyrosine 
kinases including FLT3, JAK2, and ABL [Table 1, 20,22]. Preclinical studies showed 
that AZD1152 was active against a variety of solid tumors including colon, breast, and 
lung cancers, as well as myelogenous leukemia in a tumor xenograft model [21,22]. 
These studies demonstrated phosphorylated-histone H3 as a biomarker of Aurora 
inhibition. Of note, AZD1152 potentiated the anti-tumor effects of the tubulin 
depolymerizing agent vincristine and the topoisomerase II inhibitor daunorubicin in 
AML cells in vitro and in vivo [22]. In addition, AZD1152 was able to inhibit the 
proliferation of imatinib-resistant ALL cells with Philadelphia chromosome, although it
was not active against BCR/ABL [22]. 
A recent Phase 1 trial of AZD1152 in 19 patients showed that the maximum 
tolerated dose was 200 mg, given as a 2-h weekly infusion. As with MK0457, 
neutropenia was the dose-limiting toxicity. Stable disease for longer than 25 weeks was 
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the best response achieved in three patients (one with melanoma, one with 
nasopharyngeal carcinoma and one with adenoid cystic carcinoma) [68].
MLN8054. MLN8054 is an orally available, potent and selective inhibitor of 
Aurora A kinase (IC50 4 nM versus 172 nM for Aurora A and B kinase, respectively) 
[Table 1, 23]. Exposure of cells to low concentrations of MLN8054 induced abnormal 
mitotic spindle formation and chromosomal alignment defects, characteristics of Aurora
A inhibition; however, downregulation of p-histone H3 was shown on exposure to 
higher concentrations, consistent with Aurora B inhibition. MLN8054 is currently being 
evaluated in a phase 1 trial for patients with advanced solid tumors.
PHA-739358. PHA-739358 (Nerviano Medical Sciences) is an ATP-competitive 
pan-Aurora kinase inhibitor (IC50s of 13, 79, and 61 nM for Aurora A, B, and C, 
respectively) [Table 1, 24]. As with MLN8054, phenotypic changes in cells shift from 
Aurora A to Aurora B inhibition on exposure to higher concentrations of the agent. 
PHA-739358 showed significant cross-reactivity with ABL in a biochemical assay, with 
an IC50 of 25 nM [24]. Notably, PHA-739358 was active against T315I BCR/ABL 
mutation [69]. PHA-739358 is currently being evaluated in clinical trials in solid and
hematological malignancies, including imatinib-resistant CML.
Thus, the inhibitors of Aurora kinase activity are well tolerated and produce some 
clinical benefits. Preclinical studies have found that inhibition of Aurora kinase A and B 
sensitizes malignant cells to apoptosis mediated by tubulin depolymerizing agents
[22,59]. Clinical trials are warranted to evaluate the efficacy of combining Aurora 
kinase inhibitor and this class of chemotherapeutic agents. 
5. Conclusions. Recent elucidation of the biological function of Aurora kinases in 
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normal and cancer cells has led to the development of small-molecule inhibitors. 
Preclinical as well as preliminary results of clinical trials suggest that this class of agent 
is promising for cancer treatment, although the molecular mechanisms by which 
inhibitors of Aurora kinases induce the growth arrest and apoptosis of cancer cells 
remain to be fully elucidated. Also, several issues concerning this class of agent have 
not been addressed: for example, it is not known which Aurora kinase is the best target 
for cancer treatment. Further studies are clearly required to incorporate this class of 
agent in the future treatment strategy for cancer.   
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Figure Legends.
Figure 1. Function of Aurora A kinase. (A), Aurora A phosphorylates transforming 
acid coiled-coil (TACC) proteins. The activated TACC and Aurora A are recruited to the 
centrosome and form a complex with microtubule-associated proteins such as 
Msps/XMAP215, centrosomin, and -tubulin, leading to growth of microtubules, which 
consequently promotes maturation of the centrosome. (B), Aurora A phosphorylates 
Ajuba. The phosphorylated form of Ajuba binds to Aurora A, leading to activation of 
Aurora A at late G2 phase. Aurora A and Ajuba consequently activate cyclin B1/CDK1 
complex, resulting in commitment of cells to mitosis. 
Figure 2. Function of Aurora B kinase. (A), Aurora B is activated by 
autophosphorylation after association with the passenger complex, which consists of 
inner centrosome protein (INCENP), survivin, and borealin. Activated Aurora B recruits 
pavarotti to the central spindle region during anaphase. Pavarotti is essential for 
establishment of the central spindle. (B), CENP-A is first phosphorylated on Ser7 by 
Aurora A during prophase, which recruits Aurora B to the inner centromere. Aurora B 
then maintains phosphorylation of CENP-A on Ser7 from late prophase through 
metaphase and regulates kinetochore functions. 
Table 1. Aurora kinase inhibitors.
Aurora kinase inhibitor Chemical class Aurora A IC50 Aurora B IC50 Other targets References
Hesperadin
(Boehringer Ingelheim)
Indolinone Not available 250 nM Not available 65
ZM447439
(AstraZeneca)
Quinazoline derivative 110 nM 130 nM LCK 0.88 M
SRC 1.03 M
51,67
MK0457
(Merck)
4,6 Diaminopyrimidine 0.6 nM 18 nM FLT3 30 nM 19
AZD1152
(AstraZeneca)
Quinazoline derivative 1368 nM 0.37 nM Not available 20-22,68
MLN8054
(Millennium)
Benzazepine derivative 4 nM 172 nM CHK2 28 M
PLK 53M
23
PHA-739358
(Nerviano Medical Sciences)
3-aminopyrazole derivative 13 nM 79 nM ABL 25 nM 24
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